Clinical Trial

Flu Vaccine

Study Description

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

A total of 10,650 eligible subjects (or 3,550 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over two influenza seasons (2018-2019, 2019-2020).

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - Egg based influenza vaccines

Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.

Biological - Recombinant influenza vaccines

Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.

Biological - Cell-culture based influenza vaccines

Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.

Additional Information

Official Study Title

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

Clinical Trial ID

NCT03734237

ParticipAid ID

epYR6a